Basal Innovation Team_NSM 2018

1. DEVOTE trial was conducted to

Establish the superior glycemic efficacy of insulin degludec over insulin glargine

Establish lesser risk of hypoglycemia with glargine compared to degludec

Establish the lesser insulin dose requirement and weight gain with degludec compared to glargine

Establish the cardiovascular safety of insulin degludec compared to insulin glargine

2. Which of the below figures are true for DEVOTE?

Number of trial sites from India were 36

Number of participants from India were 357

Number of countries that participated in the trial were 40

The country that recruited second highest number of participants to the trial was UK

3. Which of the below is false about DEVOTE trial

DEVOTE stands for Degludec cardiovascular outcomes trial

7637 patients were included in the trial

DEVOTE was an open label, randomized controlled trial

The number of major adverse cardiovascular outcomes that occurred in DEVOTE were 633

4. Which of the below is true about the baseline characteristics of DEVOTE?

Mean baseline HbA1c was 8.4%

Mean duration of type 2 diabetes was ~14 years

55% of the patients had established CV disease or CKD

Mean BMI was 23.4 kg/m2

5. The analysis of the primary endpoint of the DEVOTE showed that

There is a 30% significant reduction in CV outcomes with degludec compared to glargine

There is a 9% significant reduction in CV outcomes with degludec compared to glargine

There is a 9% numerical reduction in CV outcomes with degludec compared to glargine, not significant

Degludec proved cardiovascular benefits for 3-point MACE compared to glargine

6. In the DEVOTE, the incidence rates of severe hypoglycemia was

40% significantly lower with degludec Vs glargine

27% significantly lower with degludec Vs glargine

53% significantly lower with degludec Vs glargine

40% numerically lower with degludec Vs glargine, not significant

7. In the DEVOTE, the event rates of severe hypoglycemia was

40% significantly lower with degludec Vs glargine

27% significantly lower with degludec Vs glargine

53% significantly lower with degludec Vs glargine

40% numerically lower with degludec Vs glargine, not significant

8. In the DEVOTE, the event rates of nocturnal severe hypoglycemia was

40% significantly lower with degludec Vs glargine

27% significantly lower with degludec Vs glargine

53% significantly lower with degludec Vs glargine

40% numerically lower with degludec Vs glargine, not significant

9. The FPG control in DEVOTE was ______ with degludec compared to glargine

7.2 mg/dl, significantly lower

Similar

7.2 mg/dl, significantly worser

17.2 mg/dl, significantly lower

10. DEVOTE 2 trial measured which type of glycemic variability?

Day-to-day fasting glycemic variability

Within day fasting glycemic variability

Overall throughout the day glycemic variability

Post-prandial glycemic variability

11. DEVOTE 3 trial measured association between

Severe hypoglycemia and microvascular complications

Severe hypoglycemia and death

Glycemic variability and MACE

Glycemic variability and all-cause death

12. As per DEVOTE 2, patients with higher glycemic variability had

A 33% higher risk of baseline adjusted all-cause mortality

A 23% higher risk of baseline adjusted all-cause mortality

A 13% higher risk of baseline adjusted all-cause mortality

A 43% higher risk of baseline adjusted all-cause mortality

13. The DEVOTE 3 trial showed that, following an episode of severe hypoglycemia

The risk of all-cause death increased by 121% and CV death by 154%

The risk of all-cause death increased by 154% and CV death by 121%

The risk of all-cause death increased by 151% and CV death by 114%

The risk of all-cause death increased by 114% and CV death by 151%

14. Mechanism of protraction of glargine U300 is by formation of

Smaller precipitates and larger surface area

Larger precipitates and larger surface area

Smaller precipitates and smaller surface area

Larger precipitates and smaller surface area

15. Glargine U300 showed a benefit in hypoglycemia over glargine U100 in

T1D patients

Early insulin-naïve T2D patients

Patients using low dose of basal insulin

Patients using high dose of basal insulin with late diabetes

16. When compared to glargine U300, insulin degludec has

4 times higher day-to-day variability

37% lower within day variability

30% lower potency

Less even distribution of glucose lowering effect over 24 hours

17. Which of the following is untrue about the MI Basal market

Basal initiations consist the bulk of all insulin initiations

Lantus has the largest prescription share among all brands

Most prescriptions were gained by Basugine in 2017 over 2016

Tresiba® has around ~3% prescription share

18. Which of the following are true about the new switching guidelines for Tresiba?

While switching from OD Gargine U100 to Tresiba reduce dose by 20%

While switching from glargine U300 to Tresiba reduce dose by 20%

While switching from BD glargine U100 to Tresiba reduce dose by 20%

In T1D While switching from glargine U100 to Tresiba reduce dose by 20%

19. Which of the following is not a part of the Tresiba summary page in iselling?

Once daily ultra long duration of action beyond 42 hours

Similar HbA1C control to insulin glargine in treat-to-target studies

Significantly lower risk of nocturnal hypoglycaemia

21. Which of the following factors are considered for career progression from a Product Specialist to a Sr product specialist?

3P Rating

Minimum years of experience

Recommendation form Line manager

All of the above

22. Which of the following options regarding Goal Setting is completely TRUE for 2018 process:

1. Your Goal plan will remain open until Goal plan sign- off and it is recommended to have maximum 5 goals with minimum 10% weight

2. Your Goal plan will remain open until Goal plan sign- off and it is recommended to have maximum 10 goals with minimum 5% weight

3. Your Goal plan will remain open until mid-year sign- off and it is recommended to have maximum 10 goals with minimum 5% weight

4. Your Goal plan will remain open until mid-year sign- off and it is recommended to have maximum 12 goals with minimum 5% weight

23. Which of the following statements is FALSE for 2018 performance management process

Your performance rating will impact your annual salary increase

Your performance rating will not impact your selection to development programmes

Your 3P rating will serve as an input for career progression

Your performance rating will be solely decided by your manager’s discretion

25. Which of the following statements is true for 2018 Talent Development Program Nomination?

Your performance rating will be considered for your nomination

Your performance rating along with manager’ inputs will be considered for your nomination

Your cumulative health score card will be considered for your nomination

Your sales performance will be considered for your nomination

26.All employees should report any customer complaint (Product defect/AE/SAE) or safety information to

Safety Team (INAGREE@novonordisk.com)

GM (General Manager)

HQ (Head Quarters)

None of the above

27. Which of the below need to be reported ( mark the correct)

Use of NN product in pregnancy

Any technical complaint

Any adverse Event

All the above

29. In case if you observe errors in label, promotional material contact ( mark the correct)

Line Manager & QA

No need to report to any one

Distribute to HCP with error

Do not know

30. Corrections to printed or handwritten data must be made so that the original text is

Strikethrough so nothing is readable

Strikethrough but readable

Completely covered using a whitener

Enter duplicate data

31. In NN, we follow any applicable laws, regulations and industry codes. We also follow our own business ethics standards and procedures (Novo Nordisk Code of Conduct). According to the Business Ethics Code of Conduct, which of the following statements is correct?

Local law and industry code may be disregarded, if my local legal department approves it

Novo Nordisk standards and procedures may be overruled if more stringent rules apply locally

Either of the above

32. An employee invites an HCP as a speaker for a meeting to be held on 20th August 2017. You send the request for contract preparation to the legal department by filling up the contract initiation template. Amount to be paid for the services is INR 50,000. When you will calculate FMV?

At the time of payment

At the time of preparation of the contract

Either of the above

None of the above

33. In a Sponsorship, the following is acceptable:

Payment routed to HCP’s directly need not include any follow up documentation

While Sponsoring an event, commercial benefit for Novo Nordisk and disclosure of the fact that the event has been sponsored by Novo Nordisk is not required if sponsorship amount is below INR 5,00,000.00

Follow up on fund utilisation is not required if sponsorship amount is below INR 5,00,000.00

The commercial benefit to Novo Nordisk, disclosure of the fact that the event has been sponsored by Novo Nordisk, agreement and proper follow-up documentation from the institution.

34. Ryzodeg meeting took place on 1st July 2017. Timings as per agenda was 8:00 to 10:00 PM, with dinner scheduled from 9:30 to 10:00 PM. Due to unavoidable circumstances, meeting started at 8:30 PM. Meeting ended at 10:45 pm. But hotel invoice was generated at 12:00 pm. How will you abide by 75/25 rule for the scientific meeting?

I will inform Manager and pay the hotel as per his instructions

I will pay the hotel and thereafter raise exception for deviation from 25/75 rule and document the reason for delay in the start of the meeting

There is no deviation as such in the situation as it occurred due to unavoidable circumstances

None of the above

35. An employee invites a doctor (HCP) as a speaker for a meeting. The HCP accepts the invitation. He is accompanied to the meeting by his friend, who is also a doctor and practices in the field of endocrinology.

It can be accommodated as the friend is also a doctor.

Though the friend is a doctor, he has not been invited to the event by Novo Nordisk. Therefore, you should politely let the HCP know that it is not accepted as per internal policies.

Though the friend is a doctor, he has not been invited to the event by Novo Nordisk. Therefore, you should politely let the HCP know that it is not accepted as per internal policies. If the friend still attends the event, you should document it

36. What is the Incentive amount you are eligible at 100% sales achievement p.a (Both Sales & Activity)?

200000

250000

700000

None of the Above

41. Novorapid is produced by

Substitution of B29 amino acid proline with aspartic acid

Deletion of B30 amino acid threonine

Adding fatty di-acid side chain at B29 position

Substitution of B28 amino acid proline with aspartic acid

42. Pharmacokinetic profile of novorapid as compared to Actrapid:

Lesser Tmax, higher Cmax

Lesser Tmax, lesser Cmax

Higher Tmax, higher Cmax

47. In Heller study as compared to HI with Novorapid there was 72% reduction in?

Minor hypoglycemia

Nocturnal hypoglycemia

Severe nocturnal hypoglycemia

49. Select the correct inclusion criteria for Mathiesen et al.

Pregnant women upto 12 weeks of pregnancy

Pregnant women upto 08 weeks of pregnancy

Pregnant women upto 10 weeks of pregnancy

Pregnant women upto 14 weeks of pregnancy

50. Hod et al. Study gives evidence for?

IAsp use in paediatric age group

IAsp use in elderly age group

IAsp use and pregnancy

IAsp use and foetal outcome

Unlock and Upgrade

Remove all limits from your Quizzes

Basal Innovation Team_NSM 2018

More Quizzes